Results 91 to 100 of about 3,116,614 (307)
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors [PDF]
Experimental & Molecular Medicine, 2018 Sorafenib, a multikinase inhibitor with antiproliferative, antiangiogenic, and proapoptotic properties, constitutes the only effective first-line drug approved for the treatment of advanced hepatocellular carcinoma (HCC). Despite its capacity to increase survival in HCC patients, its success is quite low in the long term owing to the development of ...
Carolina Méndez-Blanco +4 more
openaire +5 more sources
Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies [PDF]
, 2019 A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione (GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism for increased GSH levels is to counteract damaging ROS to sustain the
Meierhofer, David, Xiao, Yi
core +2 more sources
Cell Death Discovery, 2023 Sorafenib (sora) is the initial therapy for patients with progressive hepatocellular carcinoma (HCC), but the emergence of drug resistance has seriously impacted its therapeutic efficacy.
Jiao Sun +5 more
semanticscholar +1 more source
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways [PDF]
, 2014 Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer’s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD þ ) from reduced nicotinamide adenine
Allison, Simon J. +6 more
core +1 more source
Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Response [PDF]
Molecular Cancer Therapeutics, 2014 We are aware that sorafenib binds to plasma proteins. At steady state, when sorafenib is orally administered at 800 mg/d, accumulation ratios are 5.7 to 6.4, indicating that it has a good distribution range.
openaire +2 more sources
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. [PDF]
, 2014 Hypertension after treatment with vascular endothelial growth factor (VEGF) receptor inhibitors is associated with superior treatment outcomes for advanced cancer patients.
Bakris, GL +13 more
core +2 more sources
International Journal on Biological Sciences, 2023 Sorafenib is a first-line chemotherapy drug for treating advanced hepatocellular carcinoma (HCC). However, its therapeutic effect has been seriously affected by the emergence of sorafenib resistance in HCC patients.
Yelin Ruan +9 more
semanticscholar +1 more source
Neoplasia: An International Journal for Oncology Research, 2014 Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC.
Jung-Chen Su +9 more
doaj +1 more source
Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity [PDF]
Cancers, 2020 Despite advances in biomedicine, the incidence and the mortality of hepatocellular carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages leading to the less than optimal outcome of the treatments. Molecular targeted therapy with sorafenib, a dual-target inhibitor targeting the serine-threonine kinase Raf and the tyrosine ...
Loraine Kay D. Cabral +2 more
openaire +2 more sources
LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells [PDF]
International Journal of Medical Sciences, 2021 Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma; vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit, and Flt-3 signaling, is approved for treatment of advanced hepatocellular carcinoma (HCC).
Ma, Yongfang +10 more
openaire +2 more sources